ORKA
Healthcare BiotechnologyOruka Therapeutics, Inc.
$84.52
+1.10 +1.32% today
Price History
Not enough data
Key Stats
Market Cap
5.60B
Avg Volume
921,579
EPS
-$2.04
52W High
$115.52
52W Low
$19.74
Div. Yield
0.0%
Analyst Ratings
Buy2
Str Buy
11
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-29.53
P/B Ratio
4.64
EV/EBITDA
-30.51
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(18.2%)
Return on Assets
(13.0%)
Liquidity & Leverage
Current Ratio
38.51
Quick Ratio
38.03
Debt / Equity
0.00
Total Cash
873.56M
Total Debt
2.55M
About
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
orukatx.com